Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-VestGlobeNewsWire • 06/14/23
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHDGlobeNewsWire • 06/08/23
Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business UpdateGlobeNewsWire • 05/10/23
Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMOGlobeNewsWire • 05/03/23
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHDGlobeNewsWire • 04/04/23
Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301GlobeNewsWire • 03/13/23
Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business UpdateGlobeNewsWire • 03/10/23
Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHDGlobeNewsWire • 02/23/23
Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHDGlobeNewsWire • 01/04/23
Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business UpdateGlobeNewsWire • 11/14/22
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHDGlobeNewsWire • 11/01/22
Cingulate Announces Agreement with Societal CDMO and Provides Clinical UpdateGlobeNewsWire • 10/24/22
Cingulate Presents Data for Its Triple-Release Buspirone Product Candidate: CTx-2103GlobeNewsWire • 09/19/22
Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business UpdateGlobeNewsWire • 08/11/22
Kansas City Business Journal Names Cingulate's Louis G. Van Horn a 2022 Chief Financial Officer of the YearGlobeNewsWire • 07/25/22